How can medical technology become more sustainable, resilient, and less dependent on fossil-based raw materials?
This question lays the foundation for the developments that lie ahead in the coming years. PFAS and similar substances will soon have no place in our healthcare system—new sustainable materials can replace them, but the question is: How and where do we start?
The cross-cluster project Sustainable Plastics 4 MedTech (SuPlaMed) is a joint initiative of the Industrial Biotechnology Cluster (CIB) and the Medical Technology Cluster (CMT) and is dedicated to getting to the bottom of this very question.
Global supply chains, fossil-based raw materials, and growing environmental regulations are increasing the pressure on companies and institutions alike to take action. At the same time, the use of plastics continues to rise—with significant consequences for the climate, the environment, and regulation. Non-recyclable waste, emissions from incineration, and the handling of problematic substances such as PFAS are increasingly coming under the spotlight of policymakers, the market, and the public.
This is where SuPlaMed comes in. The project demonstrates how bioplastics and sustainable materials can open up new avenues for a more resilient and environmentally friendly medical technology sector. The focus is on specific application areas, realistic solutions, and the question of how sustainability can become a strategic advantage. A thorough analysis and targeted dialogue between industry, research, and policy makers provide guidance and highlight potential—from technology and regulatory aspects to new business models.
SuPlaMed is aimed at everyone who wants to actively shape the future of medical technology: companies, healthcare stakeholders, scientific institutions, and regulatory decision-makers.
After all, sustainable innovation arises where perspectives converge and ideas become actionable solutions.
Discover the opportunities that sustainable materials offer for medical technology, how to address regulatory requirements early on, and how to tap into new innovation and business models for the medical technology sector.
Questions about medical technology?
